Clinical Trial: A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones

U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT06932146) titled 'A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones' on April 02.

Brief Summary: This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.

Study Start Date: March 23

Study Type: INTERVENTIONAL

Condition: Kidney Stones

Intervention: DRUG: LLX-424

Tablets for oral administration

Recruitment Status: RECRUITING

Sponsor: Lilac Therapeutics, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....